<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy</title>
    <meta name="description" content="8, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc.; In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck&#x27;s anti-PD-1 therapy, pembrolizumab.; It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic" />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy</h1>
<div class="muted">2025-09-08 17:18:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>8, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc.</li><li>In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck&#x27;s anti-PD-1 therapy, pembrolizumab.</li><li>It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic</li><li>Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47.</li><li>ABOUT PHANES THERAPEUTICS Phanes Therapeutics, Inc.</li><li>For more information about Phanes Therapeutics, please visit www.phanesthera.com.</li><li>View original content to download multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-biliary-tract-carcinoma-btc-patient-dosed-in-clinical-study-of-spevatamig-in-combination-with-chem</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/phanes-therapeutics-announces-first-biliary-171800589.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Phanes+Therapeutics+announces+first+biliary+tract+carcinoma+%28BTC%29+patient+dosed+in+clinical+study+of+spevatamig+in+combination+with+chemotherapy%0A%E2%80%A2+8%2C+2025+%2FPRNewswire%2F+--+Phanes+Therapeutics%2C+Inc.%0A%E2%80%A2+In+2023%2C+Phanes+entered+into+a+clinical+collaboration+a%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fphanes-therapeutics-announces-first-biliary-tract-carcinoma-btc-patient-dosed-in%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>